Extrahepatic manifestations of hepatitis C virus infection: Mixed cryoglobulinemia and beyond

Current Hepatitis Reports

Volumn 10, Issue 1, 2011, Pages 11-18

  Paredes, Angelo H ^a   Torres, Dawn M ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Autoimmune hemolytic anemia; Chronic hepatitis C; Chronic lymphocytic sialadenitis; Cryoglobulinemia; Extrahepatic manifestations; Glomerulonephritis; Hepatitis C virus; Interferon; Lichen planus; Necrolytic acral erythema; Ribavirin; Rituximab

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA; RIBAVIRIN; RITUXIMAB; STEROID; ZINC;

ACUTE DISEASE; ASCITES; AUTOIMMUNE HEMOLYTIC ANEMIA; CLINICAL FEATURE; COMORBIDITY; CRYOGLOBULINEMIA; CYTOPENIA; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIGESTIVE SYSTEM DISEASE; DISEASE ASSOCIATION; ENDOCRINE DISEASE; EYE DISEASE; HEART DISEASE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INSULIN RESISTANCE; KIDNEY DISEASE; LEUKOCYTOCLASTIC VASCULITIS; LICHEN PLANUS; LUNG DISEASE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MOTOR NEUROPATHY; NECROLYTIC MIGRATORY ERYTHEMA; NEPHRITIS; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; PLASMAPHERESIS; PORPHYRIA CUTANEA TARDA; REVIEW; RHEUMATIC DISEASE; SPLENIC MARGINAL ZONE LYMPHOMA; THYROID DISEASE; VASCULITIS;

EID: 79952697935     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-010-0062-2     Document Type: Review

References (54)

1. Armstrong GL, Wasley AM, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14.
2. Agnello V. Hepatitis C virus infection and type II cryoglobulinemia: an immunological perspective [published erratum appears in Hepatology 1998 Mar;27(3):889]. Hepatology 1997;26:1375-9.
3. Viganò M, Lampertico P, Rumi MG, et al. Natural history and clinical impact of cryoglobulins in chronic hepatitis C: 10-year prospective study of 343 patients. Gastroenterology 2007;133:835-42. (Pubitemid 47381359)
4. Wong VS, Egner W, Elsey T, et al. Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection. Clin Exp Immunol 1996;104:25-31. (Pubitemid 26103408)
5. Kayali Z, Buckwold VE, Simerman B, et al. Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology 2002;36:978-85.
6. De Rosa FG, Abel G, Agnello V. Observations on cryoglobulin testing: II. The association of oligoclonal mixed cryoglobulinemia with cirrhosis in patients infected with hepatitis C virus. J Rheumatol 2009;36:1956-7. Interesting article that suggests detection and quantification of type II-RF may enhance clinical monitoring of cryoglobulinemic vasculitis in HCV-infected patients.
7. Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994;19:841-8. (Pubitemid 24109343)
8. Rosa D, Saletti G, De Gregorio E, et al. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci 2005;102:18544-9. (Pubitemid 43011262)
9. Charles ED, Green RM, Marukian S, et al. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood 2008;111:1344-56. (Pubitemid 351213421)
10. Namazi MR, Kerchner KR, Pichardo RO. Essential type II mixed cryoglobulinemia causing pyoderma gangrenosum-like ulcers. ScientificWorldJournal 2008;25:228. (Pubitemid 351317531)
11. Ammendola A, Sampaolo S, Ambrosone L, et al. Peripheral neuropathy in hepatitis-related mixed cryoglobulinemia: electrophysiologic follow-up study. Muscle Nerve 2005;31:382-5. (Pubitemid 40261412)
12. Rieu V, Cohen P, Andre MH, et al. Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. Rheumatology 2002;41:290-300. (Pubitemid 34537865)
13. Iannuzzella F, Vaglio A, Garini G. Management of hepatitis C virus-related mixed cryoglobulinemia. Am J Med 2010;123:400-8. Clinically relevant review of the management of MC in HCV infection.
14. Aronsohn A, Reau N. Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol 2009;43:661-71.
15. Zuckerman E, Keren D, Slobodin G, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000;27:2172-8.
16. Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010;116:335-42.
17. Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferonalpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116:326-34.
18. Cavallo R, Roccatello D, Menegatti E, et al. Rituximab in cryoglobulinemic peripheral neuropathy. J Neurol 2009;256:1076-82.
19. Fujiwara K, Kaneko S, Kakumu S, et al. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res 2007;37:701-10. (Pubitemid 47054776)
20. Ciesek S, Steinmann E, Iken M, et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 2010;138:1875-84.
21. Ballarè M, Bobbio F, Poggi S, et al. A pilot study on the effectiveness of cyclosporine in type II mixed cryoglobulinemia. Clin Exp Rheumatol 1995;13:S201-3.
22. Ferri C, Pileri S, Zignego AL. Hepatitis C virus infection and non-Hodgkin's lymphoma. In: Geodert J. ed. Infectious Causes of Cancer. Targets for intervention. Totowa, NJ: Humana Press; 2000, 349-68.
23. Libra M, Polesel J, Russo AE, et al. Extrahepatic disorders of HCV infection: a distinct entity of B-cell neoplasia? Int J Oncol 2010;36:1331-40.
24. Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94. (Pubitemid 34753478)
25. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non- Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005;23:468-73. (Pubitemid 46224223)
26. Jalil S, Grady JJ, Lee C, et al. Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol 2010;8:297-302.
27. Fernández I, Castellano G, de Salamanca RE, et al. Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C. Scand J Gastroenterol 2003;38:314-9. (Pubitemid 36469993)
28. Nagao Y, Sata M. Hepatitis C and lichen planus. J Gastroenterol Hepatol 2004;19:1101-13.
29. Gandolfo S, Richiardi L, Carrozzo M, et al. Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: a follow-up study in an Italian population. Oral Oncol 2004;40:77-83. (Pubitemid 37510216)
30. Tabibian JH, Gerstenblith MR, Tedford RJ, et al. Necrolytic acral erythema as a cutaneous marker of hepatitis C: report of two cases and review. Dig Dis Sci 2010 May 26. Epub ahead of print. Pertinent review of necrolytic acral erythema in the setting of HCV infection.
31. Hivnor CM, Yan AC, Junkins-Hopkins JM, et al. Necrolytic acral erythema: response to combination therapy with interferon and ribavirin. J Am Acad Dermatol 2004;50:S121-4.
32. Antonelli A, Ferri C, Fallahi P, et al. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid 2007;17:447-51. (Pubitemid 46878847)
33. Torres DM, Harrison SA. Hepatitis C, insulin resistance, and steatosis. Current Hepatitis Reports 2007;6:129-37.
34. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Int Med 2000;133:592-9.
35. Dufour JF, Pradat P, Ruivard M, et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases. Eur J Gastroenterol Hepatol 2009;21:245-53. Clinically useful study that proposes a treatment algorithm for patients with autoimmune cytopenias and HCV.
36. Chiao EY, Engels EA, Kramer JR, et al. Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with HCV infection. Arch Intern Med 2009;169:357-63. Large study outlining the relationship between ITP, AHA, and HCV infection.
37. Aydeniz A, Namiduru M, Karaoglan I, et al. Rheumatic manifestations of hepatitis B and C and their association with viral load and fibrosis of the liver. Rheumatol Int 2010;30:515-7.
38. Orge E, Cefle A, Yazici A, et al. The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection. Rheumatol Int 2010;30:485-8.
39. Ramos-Casals M, Muñoz S, Medina F, et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 2009;36:1442-8.
40. Ramos-Casals M, Cervera R, Lagrutta M, et al. Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): description of 82 cases. Clin Infect Dis 2004;38:1009-16. (Pubitemid 38457211)
41. Tsui JI, Vittinghoff E, Shlipak MG, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007;167:1271-6. (Pubitemid 46998498)
42. Asrani SK, Buchanan P, Pinsky B, et al. Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol 2010;8:79-84.
43. Gordon SC, Moonka D, Brown KA, et al. Risk for renal cell carcinoma in chronic hepatitis C infection. Cancer Epidemiol Biomarkers Prev 2010;19:1066-73.
44. Matsumori A, Matoba Y, Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 1995;92:2519-25.
45. Antonelli A, Ferri C, Ferrari SM, et al. High levels of circulating N-terminal pro-brain natriuretic peptide in patients with hepatitis C. J Viral Hepat. Epub ahead of print.
46. Corey KE, Kane E, Munroe C, et al. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 2009;50:1030-7.
47. Aslam F, Alam M, Lakkis NM. Hepatitis C and carotid atherosclerosis: a retrospective analysis. Atherosclerosis. 2010;209:340-3.
48. Silva DR, Stifft J, Cheinquer H, et al. Prevalence of hepatitis C virus infection in patients with COPD. Epidemiol Infect 2010;138:167-73.
49. Kanazawa H, Hirata K, Yoshikawa J. Accelerated decline of lung function in COPD patients with chronic hepatitis C virus infection: a preliminary study based on small numbers of patients. Chest 2003;123:596-9. (Pubitemid 36269447)
50. Jain AK, Sukhija J, Saini JS, et al. Hepatitis C virus-associated keratitis. Eye 2004;18:131-4. (Pubitemid 38263460)
51. Abe T, Nakajima A, Satoh N, et al. Clinical characteristics of hepatitis C virus-associated retinopathy. Jpn J Ophthalmol 1995;39:411-9. (Pubitemid 26047964)
52. Biancone L, Pavia M, Del Vecchio Blanco G, et al. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 2001;7:287-94. (Pubitemid 33062093)
53. Acharya JN, Pacheco VH. Neurologic complications of hepatitis C. Neurologist 2008;14:151-6. Concise review of the neurologic complications associated with HCV infection.
54. Forton, DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002;35:433-9. (Pubitemid 34106386)